Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Cheol Lee

Showing results (211-220 of 226) with videos related to

Pageof 23
Sort By:
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 2, 2019
How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare CancersJi Hyun Park, Ji Sung Lee, HaYeong Koo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 21, 2023
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KRCheol-Kyu Park, Hyung-Joo Oh, Young-Chul Kim, et al.
Cancer Research|June 14, 2022
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Cancer Research|August 25, 2022
Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung CancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Cancer Research|August 26, 2022
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung CancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2008
Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry StudyKwang-Ho In, Yong-Soo Kwon, In-Jae Oh, et al.
Research (Washington, D.C.)|February 12, 2026
Tumor Exosomal L1 Cell Adhesion Molecule Promotes Brain Metastasis of Lung CancerDong Ha Kim, Chae Won Lee, Yun Jung Choi, et al.
Cancer Research and Treatment|September 1, 2022
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung CancerJang Ho Lee, Eun Young Kim, Cheol-Kyu Park, et al.
Translational Lung Cancer Research|February 9, 2026
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort studyMin Jee Kim, Junghee Jung, Wonjun Ji, et al.
Cancer Research|January 14, 2017
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung CancerJin Kyung Rho, In Yong Lee, Yun Jung Choi, et al.
Pageof 23

Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 2, 2019
How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare CancersJi Hyun Park, Ji Sung Lee, HaYeong Koo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 21, 2023
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KRCheol-Kyu Park, Hyung-Joo Oh, Young-Chul Kim, et al.
Cancer Research|June 14, 2022
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Cancer Research|August 25, 2022
Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung CancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Cancer Research|August 26, 2022
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung CancerYun Jung Choi, Da-Som Kim, Young Hoon Sung, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2008
Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry StudyKwang-Ho In, Yong-Soo Kwon, In-Jae Oh, et al.
Research (Washington, D.C.)|February 12, 2026
Tumor Exosomal L1 Cell Adhesion Molecule Promotes Brain Metastasis of Lung CancerDong Ha Kim, Chae Won Lee, Yun Jung Choi, et al.
Cancer Research and Treatment|September 1, 2022
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung CancerJang Ho Lee, Eun Young Kim, Cheol-Kyu Park, et al.
Translational Lung Cancer Research|February 9, 2026
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort studyMin Jee Kim, Junghee Jung, Wonjun Ji, et al.
Cancer Research|January 14, 2017
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung CancerJin Kyung Rho, In Yong Lee, Yun Jung Choi, et al.
Pageof 23